Theme
Private companyVertical + EnterpriseGrowth

Isomorphic Labs

Isomorphic Labs matters because it represents one of the strongest attempts to turn frontier AI research into a drug-discovery company with real pharma leverage.

HQ

London, UK

Founded

2021

Region

Europe

Current snapshot

Lifecycle position

Research

New work, prototypes, or early papers.

Preview

Selective access, early demos, or limited pilots.

Growth

Repeatable distribution, partnerships, or ecosystem pull.

Current position

Deployment

Wide production use and durable market presence.

Founded

2021

Watch cadence

Weekdays

Last verified

2026-03-31

Focus

AI-first drug discovery built on frontier biology and model-driven design

Latest move

Isomorphic Labs continues building AI drug design programs and pharmaceutical partnerships around its AlphaFold-derived research stack.

Category and subcategory context

Frontier LabsBiotechai-for-scienceResearch

Competitive context

Insilico MedicineRecursionGenerate:Biomedicines

Recent models

This profile is tracked more for products and workflow influence than for a standalone model family.

Products

AI drug design platform

Open weights

No

API access

No

Watch level

Weekdays

Signals

ScienceBiotechScientific discovery

Recent coverage of Isomorphic Labs

Recent business and product coverage pulled into the profile so you can see what is happening around the company without leaving the page.